PL372492A1 - Zmutowane białka łożyskowego czynnika wzrostu typu 1, sposób ich wytwarzania i zastosowanie - Google Patents

Zmutowane białka łożyskowego czynnika wzrostu typu 1, sposób ich wytwarzania i zastosowanie

Info

Publication number: PL372492A1
Authority: PL; Poland
Prior art keywords: preparation; growth factor; muteins; placental growth; application
Prior art date: 2002-05-17

Application number

PL03372492A

Other languages

English (en)

Other versions

PL209955B1 (pl

Inventor

Domenico Maglione

Mauro Battisti

Ettore Conti

Giuseppe Salvia

Marina Tucci

Alberto Mion

Original Assignee

Geymonat S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-17

Filing date

2003-05-19

Publication date

2005-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11456311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL372492(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-19 Application filed by Geymonat S.P.A. filed Critical Geymonat S.P.A.

2005-07-25 Publication of PL372492A1 publication Critical patent/PL372492A1/pl

2011-11-30 Publication of PL209955B1 publication Critical patent/PL209955B1/pl

Links

101000595923 Homo sapiens Placenta growth factor Proteins 0.000 title abstract 3
102100035194 Placenta growth factor Human genes 0.000 title abstract 3
238000002360 preparation method Methods 0.000 title abstract 2
239000002537 cosmetic Substances 0.000 abstract 2
230000001173 tumoral effect Effects 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000008030 elimination Effects 0.000 abstract 1
238000003379 elimination reaction Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000007170 pathology Effects 0.000 abstract 1
235000018102 proteins Nutrition 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Toxicology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Physics & Mathematics (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL372492A 2002-05-17 2003-05-19 Zmutowane białko łożyskowego czynnika wzrostu typu 1, sekwencja nukleotydowa zawierająca DNA kodujące zmutowane białko, system ekspresji, komórka gospodarza , sposób wytwarzania sekwencji nukleotydowej, sposób wytwarzania i ekstrakcji zmutowanego białka, zmutowane białko do zastosowania w sposobie leczenia, przeciwciało zdolne do rozpoznawania zmutowanego białka, kompozycja farmaceutyczna, kompozycja kosmetyczna i sposób wytwarzania kompozycji farmaceutycznej lub kosmetycznej PL209955B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2002RM000277A ITRM20020277A1 (it)	2002-05-17	2002-05-17	Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
PCT/IT2003/000296 WO2003097688A2 (en)	2002-05-17	2003-05-19	Muteins of placental growth factor type 1, preparation method and application thereof

Publications (2)

Publication Number	Publication Date
PL372492A1 true PL372492A1 (pl)	2005-07-25
PL209955B1 PL209955B1 (pl)	2011-11-30

Family

ID=11456311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL372492A PL209955B1 (pl)	2002-05-17	2003-05-19	Zmutowane białko łożyskowego czynnika wzrostu typu 1, sekwencja nukleotydowa zawierająca DNA kodujące zmutowane białko, system ekspresji, komórka gospodarza , sposób wytwarzania sekwencji nukleotydowej, sposób wytwarzania i ekstrakcji zmutowanego białka, zmutowane białko do zastosowania w sposobie leczenia, przeciwciało zdolne do rozpoznawania zmutowanego białka, kompozycja farmaceutyczna, kompozycja kosmetyczna i sposób wytwarzania kompozycji farmaceutycznej lub kosmetycznej

Country Status (21)

Country	Link
US (1)	US7314734B2 (pl)
EP (1)	EP1506295B1 (pl)
JP (1)	JP4230450B2 (pl)
KR (1)	KR101022934B1 (pl)
CN (1)	CN1323167C (pl)
AT (1)	ATE488590T1 (pl)
AU (1)	AU2003234066B2 (pl)
BR (1)	BR0309966A (pl)
CA (1)	CA2485587C (pl)
CY (1)	CY1111431T1 (pl)
DE (1)	DE60334986D1 (pl)
DK (1)	DK1506295T3 (pl)
ES (1)	ES2356360T3 (pl)
HR (1)	HRP20041178B1 (pl)
IT (1)	ITRM20020277A1 (pl)
MX (1)	MXPA04011405A (pl)
PL (1)	PL209955B1 (pl)
PT (1)	PT1506295E (pl)
RU (1)	RU2344172C2 (pl)
WO (1)	WO2003097688A2 (pl)
ZA (1)	ZA200409943B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE50309809D1 (de)	2002-11-16	2008-06-19	Dade Behring Marburg Gmbh	Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
DE102005022047A1 (de)	2005-05-09	2006-11-30	Dade Behring Marburg Gmbh	Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
JP2009100680A (ja) *	2007-10-23	2009-05-14	Univ Nagoya	ヒト全身性強皮症動物モデルの作製方法、ヒト全身性強皮症動物モデル及びその用途
EP2238448B1 (en)	2008-01-07	2016-04-06	Ortho-Clinical Diagnostics, Inc.	Calibrator/control for simultaneous assay of proteins capable of complexing with one another
US8835183B2 (en) *	2008-01-07	2014-09-16	Ortho-Clinical Diagnostics, Inc.	Determination of sFlt-1:angiogenic factor complex
EP2295449A1 (en)	2009-09-09	2011-03-16	Dompe PHA.R.MA S.p.A.	PLGF-1 in homodimeric form
CN103087153B (zh) *	2011-10-28	2015-05-06	上海市第一人民医院	一类新的抑制新生血管的小肽及其应用
WO2014191553A2 (en)	2013-05-31	2014-12-04	Cobiores Nv	Heart failure treatment
CN109134650A (zh) *	2018-09-10	2019-01-04	宁波奥丞生物科技有限公司	抗人plgf单克隆抗体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2107727C1 (ru) *	1988-03-23	1998-03-27	Яманути Фармасьютикал Ко., Лтд.	Рекомбинантный тканевой активатор плазминогена и способ его получения
IT1242149B (it) *	1990-09-27	1994-02-16	Consiglio Nazionale Ricerche	Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
EP0506477B1 (en) *	1991-03-28	1999-06-23	Merck & Co. Inc.	Vascular endothelial cell growth factor C subunit
SE9601245D0 (sv) *	1996-03-29	1996-03-29	Pharmacia Ab	Chimeric superantigens and their use
DE19748734A1 (de) *	1997-11-05	1999-05-06	Biotechnolog Forschung Gmbh	Verfahren zur Gewinnung von biologisch aktiven Dimeren von rekombinanten humanen Wachstumsfaktoren aus der Cystein-Knoten-Familie sowie Verwendung der gewonnenen Dimere
JP2003509011A (ja) *	1999-06-03	2003-03-11	ヒューマンジノームサイエンシーズ，インコーポレイテッド	脈管形成タンパク質およびそれらの使用
ES2260234T3 (es) *	2000-05-12	2006-11-01	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw.	Utilizacion de inhibidores del factor de crecimiento placentario para el tratamiento de la angiogenesis patologica, de la arteriogenesis patologica, de la inflamacion, de la formacion tumoral y/o de la perdida vascular.

2002
- 2002-05-17 IT IT2002RM000277A patent/ITRM20020277A1/it unknown
2003
- 2003-05-19 PL PL372492A patent/PL209955B1/pl unknown
- 2003-05-19 CA CA2485587A patent/CA2485587C/en not_active Expired - Fee Related
- 2003-05-19 DK DK03727958.5T patent/DK1506295T3/da active
- 2003-05-19 ES ES03727958T patent/ES2356360T3/es not_active Expired - Lifetime
- 2003-05-19 US US10/514,707 patent/US7314734B2/en not_active Expired - Fee Related
- 2003-05-19 CN CNB038112043A patent/CN1323167C/zh not_active Expired - Fee Related
- 2003-05-19 MX MXPA04011405A patent/MXPA04011405A/es active IP Right Grant
- 2003-05-19 RU RU2004137000/13A patent/RU2344172C2/ru not_active IP Right Cessation
- 2003-05-19 BR BR0309966-0A patent/BR0309966A/pt not_active IP Right Cessation
- 2003-05-19 PT PT03727958T patent/PT1506295E/pt unknown
- 2003-05-19 AU AU2003234066A patent/AU2003234066B2/en not_active Ceased
- 2003-05-19 HR HRP20041178AA patent/HRP20041178B1/hr not_active IP Right Cessation
- 2003-05-19 AT AT03727958T patent/ATE488590T1/de active
- 2003-05-19 EP EP03727958A patent/EP1506295B1/en not_active Expired - Lifetime
- 2003-05-19 KR KR1020047018601A patent/KR101022934B1/ko not_active Expired - Fee Related
- 2003-05-19 WO PCT/IT2003/000296 patent/WO2003097688A2/en not_active Ceased
- 2003-05-19 JP JP2004506360A patent/JP4230450B2/ja not_active Expired - Fee Related
- 2003-05-19 DE DE60334986T patent/DE60334986D1/de not_active Expired - Lifetime
2004
- 2004-12-08 ZA ZA2004/09943A patent/ZA200409943B/en unknown
2011
- 2011-02-16 CY CY20111100200T patent/CY1111431T1/el unknown

Also Published As

Publication number	Publication date
WO2003097688A9 (en)	2005-01-06
CA2485587C (en)	2012-08-21
WO2003097688A2 (en)	2003-11-27
KR101022934B1 (ko)	2011-03-16
US20050176634A1 (en)	2005-08-11
HK1079549A1 (en)	2006-04-07
AU2003234066A1 (en)	2003-12-02
CY1111431T1 (el)	2015-08-05
EP1506295A2 (en)	2005-02-16
AU2003234066B2 (en)	2009-04-23
DK1506295T3 (da)	2011-03-07
KR20040111639A (ko)	2004-12-31
EP1506295B1 (en)	2010-11-17
JP4230450B2 (ja)	2009-02-25
PL209955B1 (pl)	2011-11-30
MXPA04011405A (es)	2005-02-14
ATE488590T1 (de)	2010-12-15
RU2004137000A (ru)	2005-06-10
RU2344172C2 (ru)	2009-01-20
BR0309966A (pt)	2005-03-01
HRP20041178B1 (hr)	2013-11-22
ITRM20020277A1 (it)	2003-11-17
HRP20041178A2 (en)	2005-10-31
US7314734B2 (en)	2008-01-01
CN1323167C (zh)	2007-06-27
WO2003097688A3 (en)	2004-02-26
CN1653177A (zh)	2005-08-10
ITRM20020277A0 (it)	2002-05-17
PT1506295E (pt)	2011-02-23
JP2006508637A (ja)	2006-03-16
DE60334986D1 (de)	2010-12-30
ZA200409943B (en)	2005-09-28
ES2356360T3 (es)	2011-04-07
CA2485587A1 (en)	2003-11-27

Publication	Publication Date	Title
RU2009100884A (ru)	2010-07-20	Пептидные фрагменты для индукции синтеза белков внеклеточного матрикса
HUP0004560A2 (hu)	2001-04-28	Törést gyógyító PTHrP analógok
DE50004018D1 (de)	2003-11-13	Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
CA2596597A1 (en)	2006-08-10	Method for stimulation collagen synthesis and/or kgf expression
MXPA05002991A (es)	2005-10-05	Analogos de ghrh.
EP2085096A3 (en)	2009-08-12	Novel composition and methods for the treatment of immune related diseases
WO2004043361A3 (en)	2007-10-04	Compositions and methods for the treatment of natural killer cell related diseases
IL152659A (en)	2010-12-30	Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
CY1111431T1 (el)	2015-08-05	Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
PL2157192T3 (pl)	2014-01-31	Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
MY127718A (en)	2006-12-29	Dolastatin 10 derivatives.
DE602006020898D1 (de)	2011-05-05	Peptide zur förderung des haarwachstums und zur verbesserung von falten und kosmetische zusammensetzungen, die diese enthalten
IL158013A (en)	2010-12-30	Isolated polypeptide and pharmaceutical composition comprising it for the diagnosis of retinal dystrophy and use thereof in the preparation of a medicament for the treatment of retinal dystrophy
CN116802190A (zh)	2023-09-22	特异于转铁蛋白受体1（TfR1）的双环肽配体
ATE211391T1 (de)	2002-01-15	Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
KR950032165A (ko)	1995-12-20	토코페롤 유도체
FR2846883B1 (fr)	2004-12-24	Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide
DE60100500D1 (de)	2003-08-28	Suspension enthaltend ein epi-hne protein, verfahren zu ihrer herstellung, daraus hergestelltes trockenpulveraerosol, arzneimittelzusammensetzungen enthaltend diese suspension oder dieses aerosol und ihre verwendungen
EA038745B1 (ru)	2021-10-13	Конъюгат миноксидила и пептида
AU2003271811A8 (en)	2004-02-02	Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
AU2003292326A1 (en)	2004-06-03	Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
KR940007059A (ko)	1994-04-26	변형된 혈소판 인자-4
DE69834929D1 (de)	2006-07-27	Verwendung eines organspezifischen ernährungmittels
TW200733897A (en)	2007-09-16	Oral product for moistening skin
JP6312191B2 (ja)	2018-04-18	血管弛緩作用を有するペプチド及び血管弛緩剤